X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): N,N-Dimethyltryptamine
Therapeutic Area: Neurology Product Name: AP-188
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2021
Details:
The Company announced preclinical study of AP-188 (“N, N-Dimethyltryptamine) in stroke patients which is now underway with Charles River Laboratories.The planned Phase 1 study will investigate the safety, tolerability and pharmacokinetics of intravenous DMT infusion.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): N,N-Dimethyltryptamine
Therapeutic Area: Neurology Product Name: AP-188
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2021
Details:
Algernon has filed new provisional patents for new forms of N,N-Dimethyltryptamine (DMT), in addition to formulation, dosage and method of use claims for ischemic stroke. The Company has also filed claims for combination therapy of DMT and Constraint Induced Movement Therapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): N,N-Dimethyltryptamine
Therapeutic Area: Neurology Product Name: AP-188
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2021
Details:
28% and 32% significant reductions in first and total strokes, respectively, Showed with VASCEPA compared to placebo and reductions in fi
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
